Anaptysbio Stock Performance
| ANAB Stock | USD 47.85 0.40 0.84% |
On a scale of 0 to 100, AnaptysBio holds a performance score of 10. The firm shows a Beta (market volatility) of -0.68, which signifies possible diversification benefits within a given portfolio. As returns on the market increase, returns on owning AnaptysBio are expected to decrease at a much lower rate. During the bear market, AnaptysBio is likely to outperform the market. Please check AnaptysBio's mean deviation, standard deviation, treynor ratio, as well as the relationship between the downside deviation and total risk alpha , to make a quick decision on whether AnaptysBio's price patterns will revert.
Risk-Adjusted Performance
Fair
Weak | Strong |
Compared to the overall equity markets, risk-adjusted returns on investments in AnaptysBio are ranked lower than 10 (%) of all global equities and portfolios over the last 90 days. Despite somewhat weak basic indicators, AnaptysBio sustained solid returns over the last few months and may actually be approaching a breakup point. ...more
Actual Historical Performance (%)
One Day Return 0.84 | Five Day Return 1.81 | Year To Date Return 6.45 | Ten Year Return 181.47 | All Time Return 181.47 |
1 | AnaptysBio To Save 10 Million After Discontinuing Ulcerative Colitis Study | 11/10/2025 |
2 | AnaptysBio initiates litigation against GSK subsidiary Tesaro ANABGSK | 11/21/2025 |
3 | Disposition of 6360 shares by Dennis Mulroy of AnaptysBio at 45.2062 subject to Rule 16b-3 | 12/16/2025 |
4 | Disposition of 10000 shares by Eric Loumeau of AnaptysBio at 51.0 subject to Rule 16b-3 | 12/22/2025 |
5 | Disposition of 1500 shares by Lizzul Paul F. of AnaptysBio at 50.0 subject to Rule 16b-3 | 12/26/2025 |
6 | Trade Alert Independent Director Of AnaptysBio J. Ware Has Sold Stock | 12/30/2025 |
7 | Disposition of 7287 shares by Eric Loumeau of AnaptysBio subject to Rule 16b-3 | 01/02/2026 |
8 | Disposition of 2983 shares by Eric Loumeau of AnaptysBio at 43.26 subject to Rule 16b-3 | 01/05/2026 |
9 | Acquisition by Orwin John A of 6000 shares of AnaptysBio subject to Rule 16b-3 | 01/06/2026 |
10 | Disposition of 1908 shares by Dennis Mulroy of AnaptysBio at 45.11 subject to Rule 16b-3 | 01/07/2026 |
11 | Anaptys Files Motion to Dismiss Tesaros Claim of Anticipatory Breach of Contract in Ongoing Litigation Against Tesaro, a GSK subsidiary | 01/08/2026 |
12 | What AnaptysBio s Royalty Spin-Off Plan Means For Shareholders | 01/09/2026 |
13 | Disposition of 11000 shares by Marquet Magda of AnaptysBio at 26.11 subject to Rule 16b-3 | 01/15/2026 |
| Begin Period Cash Flow | 36 M | |
| Total Cashflows From Investing Activities | 95.4 M |
AnaptysBio | Build AI portfolio with AnaptysBio Stock |
AnaptysBio Relative Risk vs. Return Landscape
If you would invest 3,658 in AnaptysBio on October 31, 2025 and sell it today you would earn a total of 1,127 from holding AnaptysBio or generate 30.81% return on investment over 90 days. AnaptysBio is currently generating 0.5141% in daily expected returns and assumes 3.8097% risk (volatility on return distribution) over the 90 days horizon. In different words, 34% of stocks are less volatile than AnaptysBio, and 90% of all traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
AnaptysBio Target Price Odds to finish over Current Price
The tendency of AnaptysBio Stock price to converge on an average value over time is a known aspect in finance that investors have used since the beginning of the stock market for forecasting. However, many studies suggest that some traded equity instruments are consistently mispriced before traders' demand and supply correct the spread. One possible conclusion to this anomaly is that these stocks have additional risk, for which investors demand compensation in the form of extra returns.
| Current Price | Horizon | Target Price | Odds to move above the current price in 90 days |
| 47.85 | 90 days | 47.85 | about 17.36 |
Based on a normal probability distribution, the odds of AnaptysBio to move above the current price in 90 days from now is about 17.36 (This AnaptysBio probability density function shows the probability of AnaptysBio Stock to fall within a particular range of prices over 90 days) .
Given the investment horizon of 90 days AnaptysBio has a beta of -0.68. This suggests as returns on the benchmark increase, returns on holding AnaptysBio are expected to decrease at a much lower rate. During a bear market, however, AnaptysBio is likely to outperform the market. Additionally AnaptysBio has an alpha of 0.5648, implying that it can generate a 0.56 percent excess return over Dow Jones Industrial after adjusting for the inherited market risk (beta). AnaptysBio Price Density |
| Price |
Predictive Modules for AnaptysBio
There are currently many different techniques concerning forecasting the market as a whole, as well as predicting future values of individual securities such as AnaptysBio. Regardless of method or technology, however, to accurately forecast the stock market is more a matter of luck rather than a particular technique. Nevertheless, trying to predict the stock market accurately is still an essential part of the overall investment decision process. Using different forecasting techniques and comparing the results might improve your chances of accuracy even though unexpected events may often change the market sentiment and impact your forecasting results.AnaptysBio Risk Indicators
For the most part, the last 10-20 years have been a very volatile time for the stock market. AnaptysBio is not an exception. The market had few large corrections towards the AnaptysBio's value, including both sudden drops in prices as well as massive rallies. These swings have made and broken many portfolios. An investor can limit the violent swings in their portfolio by implementing a hedging strategy designed to limit downside losses. If you hold AnaptysBio, one way to have your portfolio be protected is to always look up for changing volatility and market elasticity of AnaptysBio within the framework of very fundamental risk indicators.α | Alpha over Dow Jones | 0.56 | |
β | Beta against Dow Jones | -0.68 | |
σ | Overall volatility | 5.35 | |
Ir | Information ratio | 0.13 |
AnaptysBio Alerts and Suggestions
In today's market, stock alerts give investors the competitive edge they need to time the market and increase returns. Checking the ongoing alerts of AnaptysBio for significant developments is a great way to find new opportunities for your next move. Suggestions and notifications for AnaptysBio can help investors quickly react to important events or material changes in technical or fundamental conditions and significant headlines that can affect investment decisions.| AnaptysBio appears to be risky and price may revert if volatility continues | |
| The company reported the previous year's revenue of 91.28 M. Net Loss for the year was (145.23 M) with profit before overhead, payroll, taxes, and interest of 16.47 M. | |
| AnaptysBio currently holds about 442.15 M in cash with (135.34 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 15.66. | |
| Over 94.0% of the company shares are held by institutions such as insurance companies | |
| Latest headline from MacroaxisInsider: Disposition of 6360 shares by Dennis Mulroy of AnaptysBio at 45.2062 subject to Rule 16b-3 |
AnaptysBio Price Density Drivers
Market volatility will typically increase when nervous long traders begin to feel the short-sellers pressure to drive the market lower. The future price of AnaptysBio Stock often depends not only on the future outlook of the current and potential AnaptysBio's investors but also on the ongoing dynamics between investors with different trading styles. Because the market risk indicators may have small false signals, it is better to identify suitable times to hedge a portfolio using different long/short signals. AnaptysBio's indicators that are reflective of the short sentiment are summarized in the table below.
| Common Stock Shares Outstanding | 28.4 M | |
| Cash And Short Term Investments | 385.4 M |
AnaptysBio Fundamentals Growth
AnaptysBio Stock prices reflect investors' perceptions of the future prospects and financial health of AnaptysBio, and AnaptysBio fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on AnaptysBio Stock performance.
| Return On Equity | -3.08 | ||||
| Return On Asset | -0.0423 | ||||
| Profit Margin | (0.50) % | ||||
| Operating Margin | 0.45 % | ||||
| Current Valuation | 1.08 B | ||||
| Shares Outstanding | 27.69 M | ||||
| Price To Earning | 81.21 X | ||||
| Price To Book | 114.73 X | ||||
| Price To Sales | 7.83 X | ||||
| Revenue | 91.28 M | ||||
| Gross Profit | 16.47 M | ||||
| EBITDA | (92.74 M) | ||||
| Net Income | (145.23 M) | ||||
| Cash And Equivalents | 442.15 M | ||||
| Cash Per Share | 15.66 X | ||||
| Total Debt | 369.46 M | ||||
| Debt To Equity | 0.07 % | ||||
| Current Ratio | 22.79 X | ||||
| Book Value Per Share | (1.07) X | ||||
| Cash Flow From Operations | (135.34 M) | ||||
| Earnings Per Share | (2.82) X | ||||
| Market Capitalization | 1.33 B | ||||
| Total Asset | 483.83 M | ||||
| Retained Earnings | (759.33 M) | ||||
| Working Capital | 386.45 M | ||||
| Current Asset | 297.84 M | ||||
| Current Liabilities | 16.6 M | ||||
About AnaptysBio Performance
By analyzing AnaptysBio's fundamental ratios, stakeholders can gain valuable insights into AnaptysBio's financial health, operational efficiency, and overall profitability, helping them make informed investment and management decisions. For instance, if AnaptysBio has a high ROA and ROE, it suggests that the company is efficiently using its assets and equity to generate substantial profits, making it an attractive investment. Conversely, if AnaptysBio has a low ROA and ROE, it may indicate underlying issues in asset and equity management, signaling a need for operational improvements.
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | (0.27) | (0.28) | |
| Return On Capital Employed | (0.24) | (0.25) | |
| Return On Assets | (0.27) | (0.28) | |
| Return On Equity | (1.84) | (1.94) |
Things to note about AnaptysBio performance evaluation
Checking the ongoing alerts about AnaptysBio for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for AnaptysBio help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| AnaptysBio appears to be risky and price may revert if volatility continues | |
| The company reported the previous year's revenue of 91.28 M. Net Loss for the year was (145.23 M) with profit before overhead, payroll, taxes, and interest of 16.47 M. | |
| AnaptysBio currently holds about 442.15 M in cash with (135.34 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 15.66. | |
| Over 94.0% of the company shares are held by institutions such as insurance companies | |
| Latest headline from MacroaxisInsider: Disposition of 6360 shares by Dennis Mulroy of AnaptysBio at 45.2062 subject to Rule 16b-3 |
- Analyzing AnaptysBio's financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether AnaptysBio's stock is overvalued or undervalued compared to its peers.
- Examining AnaptysBio's industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating AnaptysBio's management team can have a significant impact on its success or failure. Reviewing the track record and experience of AnaptysBio's management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of AnaptysBio's stock. These opinions can provide insight into AnaptysBio's potential for growth and whether the stock is currently undervalued or overvalued.
Complementary Tools for AnaptysBio Stock analysis
When running AnaptysBio's price analysis, check to measure AnaptysBio's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy AnaptysBio is operating at the current time. Most of AnaptysBio's value examination focuses on studying past and present price action to predict the probability of AnaptysBio's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move AnaptysBio's price. Additionally, you may evaluate how the addition of AnaptysBio to your portfolios can decrease your overall portfolio volatility.
| Portfolio Diagnostics Use generated alerts and portfolio events aggregator to diagnose current holdings | |
| Crypto Correlations Use cryptocurrency correlation module to diversify your cryptocurrency portfolio across multiple coins | |
| Analyst Advice Analyst recommendations and target price estimates broken down by several categories | |
| Equity Search Search for actively traded equities including funds and ETFs from over 30 global markets | |
| Bonds Directory Find actively traded corporate debentures issued by US companies | |
| Portfolio Analyzer Portfolio analysis module that provides access to portfolio diagnostics and optimization engine |